Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2010

View Archived Issues

Fampridine therapy increases walking speed of patients with MS in phase II/III trials

Combination of WX-671 and gemcitabine shows promise in phase II trial in pancreatic cancer

AR-452530 and AR-460770 reduce symptoms of EAE in vivo

BETAPEDIC trial of IFN-beta-1b in juvenile patients with MS is enrolling participants

Rifaximin-EIR induces durable remissions in patients with Crohn's disease

Novel fused piperidines identified by Kowa

Eisai discontinues development of antiobesity drug KES-524

Validation of DM-199 shown by significantly increasing insulin sensitivity

Caprion identifies protein biomarkers to predict response to HCV treatment

New metabotropic glutamate mGlu5 receptor ligands claimed

Gilead Sciences announces third quarter highlights

Shionogi patents novel inhibitors of cap-dependent endonuclease

Nippon Chemiphar claims new PPAR-delta receptor agonists

Astellas applies for Japanese marketing approval for degarelix for prostate cancer

BioDelivery Sciences meets with FDA for BEMA Buprenorphine in chronic pain

Febuxostat launched for hyperuricemia in Canada

E.U. grants authorization for Ruconest in hereditary angioedema

Evotec licenses EVT-201 to Jingxin Pharma

Biotie and Roche to terminate research and option agreement for SSAO inhibitors

New trial begins of Octapharma's rFVIII derived from a human cell line

Sunovion receives FDA approval for its once-daily schizophrenia treatment Latuda

Amira begins phase I trial of new lysophospholipid LPA1 receptor antagonist

Pharmasset's PSI-938 demonstrates antiviral activity in phase I trial

FDA approves Sprycel for treatment of newly diagnosed Ph+ CML in chronic phase

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...